AUS
NZ
UK
CA
USA
IND
Highlights
Medical and consumer product companies with significant North American exposure have experienced considerable share price declines following newly announced tariff measures. The announcement of a 34 per cent tariff increase on goods manufactured in China has heightened concerns that U.S.-based retailers will be forced to raise prices, putting margin pressure on Australian exporters and companies with China-based production lines.
Ansell Limited (ASX:ANN), a global manufacturer of medical gloves and protective equipment, experienced a sharp decline of 12.5 per cent in early trading. The sell-off follows recent investor updates in which the company outlined its strategy to offset tariff pressures through price adjustments. In February, Ansell flagged intentions to relocate part of its manufacturing operations away from China in a move aimed at mitigating the impact of geopolitical headwinds and rising trade barriers. The tariff increase has cast fresh uncertainty over the company’s ability to deliver on its earnings guidance, particularly given the cost-sensitive nature of its medical and industrial clientele.
Breville Group Ltd (ASX:BRG), known for its kitchen appliances and consumer electronics, also recorded steep losses. Shares in the company fell as much as 10 per cent before recovering slightly to a 5.8 per cent decline by the end of the session. The business generates a substantial portion of its revenue from the United States, and the rise in tariffs is expected to impact input costs and product pricing. Breville’s supply chain, which includes manufacturing components sourced from China, places it squarely in the crosshairs of the new import levies. Any cost increases could affect competitiveness in an already price-sensitive retail market in North America.
Lovisa Holdings Ltd (ASX:LOV), a fast-fashion jewellery retailer with global operations, was also impacted by the announcement, dropping 6.2 per cent. The company operates in multiple international markets, including the U.S., and like its peers, is vulnerable to fluctuations in input costs driven by geopolitical tensions. While Lovisa has not released a formal statement regarding the tariffs, market reaction indicates growing apprehension over potential disruptions to its cost structure and margins.
The broader implications of these tariff measures extend beyond individual company impacts. Australian exporters that manufacture goods in China or rely on sales to the U.S. face a dual challenge: managing higher input costs while navigating uncertain consumer demand. For companies with limited pricing power, absorbing these costs internally may erode profitability. Those opting to pass costs on to consumers risk dampening demand in key international markets.
Further compounding the issue is the complexity of global supply chains. Reshoring or relocating manufacturing out of China is a process that requires significant capital investment, operational risk assessments, and time. While some companies such as Ansell have flagged such moves, the short-term financial consequences remain uncertain, especially under a volatile macroeconomic environment.
In addition to tariff risks, the potential for retaliatory measures or further escalation in trade tensions poses a lingering threat to sentiment. With tariff policy being shaped by political dynamics, companies are grappling with the challenge of planning under an increasingly unpredictable regulatory landscape.
As the U.S. heads into an election cycle, policy shifts—particularly in relation to China—remain a pivotal risk factor for Australian firms heavily linked to American markets. This renewed focus on tariffs is likely to prompt further scrutiny of supply chain exposure and geographic revenue diversification in future earnings announcements.
The steep share price reactions seen in Ansell Limited (ASX:ANN), Breville Group Ltd (ASX:BRG), and Lovisa Holdings Ltd (ASX:LOV) reflect heightened sensitivity to trade policy developments and underline the critical importance of proactive risk management in a globalised economy. The ability of these companies to navigate the evolving tariff landscape, protect margins, and maintain growth trajectories will remain a central concern for stakeholders in the months ahead.
